Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study

Type B ◽

Open Label ◽

Phase 3 ◽

A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6–64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines

Vaccine ◽

10.1016/j.vaccine.2021.08.106 ◽

2021 ◽

Author(s):

Yoshitaka Yamazaki ◽

Masanori Ikeda ◽

Takayuki Imada ◽

Kenji Furuno ◽

Tomoyuki Mizukami ◽

...

Keyword(s):

Single Dose ◽

Conjugate Vaccine ◽

Pneumococcal Disease ◽

Pneumococcal Vaccines ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Increased Risk

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial

Vaccine ◽

10.1016/j.vaccine.2012.12.066 ◽

2013 ◽

Vol 31 (9) ◽

pp. 1284-1292 ◽

Cited By ~ 6

Author(s):

Sven Arne Silfverdal ◽

Carl-Erik Flodmark ◽

Lars Rombo ◽

Susan P. Tansey ◽

Mohinder Sidhu ◽

...

Keyword(s):

Conjugate Vaccine ◽

Open Label ◽

Phase 3 ◽

Open Label Trial

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) Administered in a 2+1 Schedule to Healthy Infants

Case Medical Research ◽

10.31525/ct1-nct03896477 ◽

2019 ◽

Author(s):

Keyword(s):

Conjugate Vaccine ◽

Phase 3 ◽

Healthy Infants

Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006635.793477611 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356324.793557555 ◽

2019 ◽

Author(s):

Jose Biller

Keyword(s):

Acute Stroke ◽

Antiplatelet Therapy ◽

Standard Care ◽

Platelet Transfusion ◽

Cerebral Haemorrhage ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726438889.793525325 ◽

2016 ◽

Author(s):

Stefan Bielack

Keyword(s):

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Oesophageal Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736675072.793566801 ◽

2019 ◽

Author(s):

Pedro Legua Leiva

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Randomised Controlled

Faculty Opinions recommendation of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737782327.793577733 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Randomised Controlled Trial ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled